ATS 2019 Virtual Final Program

10:15 Safety and Efficacy of Transplantation of High Cumulative Dose Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Patients with Idiopathic Pulmonary Fibrosis and Rapid Lung Function Decline/ A. Averyanov, I. Koroleva, A. Sotnikova, M. Konoplyannikov, V. Lesnyak, O. Danilevskaya, V. Baklaushev, Moscow, Russian Federation, p.A2640 10:30 Epidemiology and Effect of Therapy in Patients with Interstitial Pneumonia with Autoimmune Features (IPAF)/ P.-V. Mari, S. Kay, E. Belloli, J.S.V. Sheth, M.L. Salisbury, C. Holtze, B. Wang, J.L. Myers, K. Konopka, A. Lagstein, E. Kazerooni, A. Chughtai, D. Vummidi, V. Nagaraja, D. Khanna, K.R. Flaherty, L. Richeldi, E.S. White, Rome, Italy, p.A2641 10:45 Effects of Anticoagulation on Survival in Interstitial Lung Disease: An Analysis of the Pulmonary Fibrosis Foundation (PFF) Registry/ C.S. King, E. Freiheit, A.W. Brown, O.A. Shlobin, D. Venuto, S.D. Nathan, Falls Church, VA, p.A2642 11:00 Nintedanib Reduces Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Results of the SENSCIS Trial/ O. Distler, K.B. Highland, M. Gahlemann, A. Azuma, A. Fischer, M.D. Mayes, G. Raghu, W. Sauter, M. Girard, M. Alves, E. Clerisme-Beaty, S. Stowasser, K. Tetzlaff, M. Kuwana, T.M. Maher, Zurich, Switzerland, p.A7360 BEHAVIORAL MINI SYMPOSIUM B18 ENHANCING QUALITY OF LIFE AND DISEASE MANAGEMENT IN PULMONARY CONDITIONS 9:15 a.m. - 11:15 a.m. KBHCCD Room D162/D164 (Level 1) Chairing: P.M. Meek, PhD, RN,BC, ATSF, Aurora, CO N.E. Bracken, ACNPC, MSN, Chicago, IL Oral Presentations 9:15 The Impact of a Multicomponent Integrative Intervention on Symptoms and Health Related Quality of Life for Patients with Pulmonary Hypertension/ T.T. Von Visger, S. Thrane, M.D. Klatt, A. DeVito Dabbs, L.L. Chlan, M.B. Happ, Columbus, OH, p.A2643 9:30 COPD Hospital Admission Reduction Playbook: Incorporating Telehealth in the Home/ A. Dowe, B. Finn, S. Lawani, E. Lindholm, Middletown, CT, p.A2644 9:45 Effect of Physical Activity Coaching on Acute Care Utilization and Survival in COPD: A Pragmatic Controlled Trial (Walk On!)/ H.Q. Nguyen, I.-L.A. Liu, M. Moy, V.S. Fan, M.K. Gould, S. Desai, W. Towner, G. Yuen, J.S. Lee, S.J. Park, A.H. Xiang, Pasadena, CA, p.A2645 10:00 Measuring Sedentary Behavior in People with Chronic Obstructive Pulmonary Disease (COPD)/ J.L. Larson, K. Webster, R. Dechert, Ann Arbor, MI, p.A2646 10:15 A Descriptive Study of Multi-Morbidity in Chronic Obstructive Pulmonary Disease (COPD) Across Three Geographic Regions of a Large Integrated Healthcare System/ H.Q. Nguyen, E. Shen, B. Creekmur, J.S. Lee, R.A. Mularski, A.S. Go, P. Crawford, G.H. Tabada, M.K. Gould, Pasadena, CA, p.A2647 10:30 The Effect of CPAP Use on Insomnia Among Persons with Type 2 Diabetes and Obstructive Sleep Apnea/ L. Baniak, S.S. Sereika, Z. Bizhanova, C.W. Atwood, J.L. Morris, R.C. Stansbury, P.J. Strollo, E.R. Chasens, Pittsburgh, PA, p.A2648 10:45 A Qualitative Study of Enablers and Barriers to Participation and Retention in Cancer Research/ G.L. Narsavage, T. Petitte, A. Nichols, Morgantown, WV, p.A2649 BASIC • CLINICAL • TRANSLATIONAL MINI SYMPOSIUM B19 ADVANCES IN THE TREATMENT OF NTM 9:15 a.m. - 11:15 a.m. KBHCCD Ballroom A Two (Level 2) Chairing: K.L. Winthrop, MD, MPH, Portland, OR R. Thomson, MBBS, PhD, Greenslopes, Australia D.E. Griffith, MD, Tyler, TX Oral Presentations 9:15 Comparing Treatment and Outcomes Between Mycobacterium Xenopi and Mycobacterium Avium Complex Patients with Nodular Bronchiectatic and Fibrocavitary Radiologic Patterns/ A. Zaheen, T. Hirama, M. Mehrabi, S.K. Brode, T.K. Marras, Toronto, Canada, p.A2650 9:30 The Impact of Different Antibiotic Treatment Regimens on Mortality in Mycobacterium Avium Complex Pulmonary Disease (MAC-PD): A Population Based Study/ S.K. Brode, H. Chung, M. Campitelli, J. Kwong, A. Marchand-Austin, K.L. Winthrop, F. Jamieson, T.K. Marras, Toronto, Canada, p.A2651 9:45 In Vitro Activity of New Tetracycline Analogues Eravacycline and Omadacycline Against Drug-Resistant Mycobacterium Abscessus Clinical Isolates/ A. Kaushik, E.L. Nuermberger, Baltimore, MD, p.A2652 10:00 Open-Label Trial of Amikacin Liposome Inhalation Suspension in M. Abscessus Lung Disease/ S. Siegel, J.A. Clock, J. Hoeft, B. Chan, P. Sullivan, J. Philley, L.C. Strnad, D.E. Griffith, K.L. Winthrop, Portland, OR, p.A2653 10:15 Pharmacokinetic (PK) Evaluation of Amikacin Liposome Inhalation Suspension (ALIS) in Patients with Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease/ C.M. Rubino, N. Onufrak, D.E. Griffith, S.M. Bhavnani, G. Eagle, K.L. Winthrop, Schenectady, NY, p.A2654 10:30 Treatment of M. Abscessus Complex: An Investigation of the Efficacy of Inhaled Forms of Amikacin/ J. Clock, A. Brunton, S.A.R. Siegel, K.L. Winthrop, L.C. Strnad, Portland, OR, p.A2655 ATS 2019 • Dallas, TX 132 MONDAY • MAY 20